Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Lantheus Holdings, Inc. (LNTH) Guidance & Earnings Results

On 2026-08-06 Lantheus Holdings, Inc. issued guidance: "Guidance suspended due to pending…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

LNTHLantheus Holdings, Inc.Follow LNTH — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
6.5B
P/E TTM
24.2
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
6 Aug 26—Guidance suspended due to pending transaction
7 May 26ReaffirmedFull year 2026 revenue and adjusted EPS guidance reaffirmed · full year
26 Feb 26RaisedFY2026 revenue $1.4B-$1.45B; adjusted EPS $5.00-$5.25 · full year
6 Nov 25MixedUpdated full-year 2025 revenue and adjusted EPS guidance reflecting Life Molecular Imaging acquisition · full year
6 Aug 25RaisedUpdated FY2025 guidance for revenue and adjusted diluted EPS reflecting Life Molecular Imaging acquisition. · full year

Lantheus Holdings, Inc. — questions

What guidance did Lantheus Holdings, Inc. give?
On 2026-08-06: "Guidance suspended due to pending transaction"
When does Lantheus Holdings, Inc. report earnings?
Lantheus Holdings, Inc.'s next earnings report is expected on 2026-10-29.

Every figure on this page comes from Lantheus Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.